SLC6A1variants identified in epilepsy patients reduce γ‐aminobutyric acid transport

Citations Over TimeTop 10% of 2018 papers

Abstract

Previous reports have identified SLC6A1 variants in patients with generalized epilepsies, such as myoclonic-atonic epilepsy and childhood absence epilepsy. However, to date, none of the identified SLC6A1 variants has been functionally tested for an effect on GAT-1 transporter activity. The purpose of this study was to determine the incidence of SLC6A1 variants in 460 unselected epilepsy patients and to evaluate the impact of the identified variants on γ-aminobutyric acid (GABA)transport. Targeted resequencing was used to screen 460 unselected epilepsy patients for variants in SLC6A1. Five missense variants, one in-frame deletion, one nonsense variant, and one intronic splice-site variant were identified, representing a 1.7% diagnostic yield. Using a [3 H]-GABA transport assay, the seven identified exonic variants were found to reduce GABA transport activity. A minigene splicing assay revealed that the splice-site variant disrupted canonical splicing of exon 9 in the mRNA transcript, leading to premature protein truncation. These findings demonstrate that SLC6A1 is an important contributor to childhood epilepsy and that reduced GAT-1 function is a common consequence of epilepsy-causing SLC6A1 variants.

Related Papers

• → Efficient Modulation of Exon Skipping via Antisense Circular RNAs(2023)33 cited
• → Six Exonic Variants in the SLC5A2 Gene Cause Exon Skipping in a Minigene Assay(2020)32 cited
• → Exon identity influences splicing induced by exonic variants and in silico prediction efficacy(2020)9 cited
• → Single‐nucleotide substitution T to A in the polypyrimidine stretch at the splice acceptor site of intron 9 causes exon 10 skipping in the ACAT1 gene(2017)6 cited
• → The qMini assay identifies an overlooked class of splice variants(2023)1 cited